CXCR2 and neoplasm: However, combined CCR2 and CXCR2 blockade led to a sustained inhibition of systemic mobilization of both CCR2+ TAMs and CXCR2+ neutrophils, which enabled anti-tumor immune response and potentiated FOLFIRINOX chemotherapy.